Comment from Allied Safety and Health LLC

Summary: Alison Thierry-Hunt, President of Allied Safety and Health, LLC, supports the FDA's consideration to exempt certain Class II clinical toxicology devices from premarket notification. The commenter argues that the current 510(k) clearance requirement creates unnecessary barriers for drug testing and collection devices to enter the federal marketplace.